Obvious there is going to be a frenzy of buying offset by offloading of some longterm holds well into the money when it lists. There are many aspects to consider. Eg., the Keytruda combo. If Merck want to TT to bolster their 10 billion blockbuster drug they should be made to pay through the nose. Its not only melanoma that comes into the equation. An indication for Keytruda is head and neck cancers, specifically HNSCC, which Qbiotics are targeting in trials (phase 1/11) in Oz and especially India aligned with its largest multinational TATA. China next. And obviously others like the very significant breast cancer and so on. Throw in the wound healing on the human side and who knows where this will go, especially as they have other possible even likely very promising drugs. Then there is the vet side of things. Given Virbac's seeing is believing theme they are promoting, maybe the price in a few years time will need to seen to believed. If Keytruda is worth 10 bill and seeing how much TT boosts its efficacy and survival rate in mice, 2x at least, and how safe TT is, how much really is TT alone worth in the human market?.On the proviso the results follow the current trend. So far we have not seen anything to indicate otherwise. Yes my view obviously. Appreciate the support. Cheers
